Clinical cancer research, 2002-12, Vol.8 (12), p.3803-3812
2002
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- RANTES Expression Is a Predictor of Survival in Stage I Lung Adenocarcinoma
- Ist Teil von
- Clinical cancer research, 2002-12, Vol.8 (12), p.3803-3812
- Ort / Verlag
- Philadelphia, PA: American Association for Cancer Research
- Erscheinungsjahr
- 2002
- Quelle
- Free E-Journal (出版社公開部分のみ）
- Beschreibungen/Notizen
- Purpose: The presence of an active lymphocytic response (ALR) in non-small cell lung cancer (NSCLC) tumors has previously been associated with a more favorable prognosis. The purpose of this study was to identify differences in global gene expression profiles between stage I NSCLC tumors with ALR (ALR+) and those without ALR (ALR−). Experimental Design: Sixty-three stage I lung adenocarcinomas were analyzed for gene expression using Affymetrix oligonucleotide microarrays. Tumors were stratified into ALR+ and ALR− groups and compared for statistically significant differences in gene expression. Identified candidate genes were validated using both ELISA and immunohistochemistry. Follow-up data for these patients were collected and used to assess patient prognosis. Results: Of the 63 tumors studied, 27 were ALR+ and 36 were ALR−. A total of 303 genes showed significant differences in gene expression between the two populations ( t test, P < 0.02). Three of the genes overexpressed by ALR+ tumors were the chemokines: small inducible cytokine A4 ( MIP-1 β), RANTES , and interferon inducible protein 10 ( IP-10 ). Immunohistochemistry analysis showed that the tumor cells expressed these cytokines. ELISA showed that MIP-1β and RANTES were overexpressed at the protein level by ALR+ tumors. Univariate Cox proportional hazards analysis showed that RANTES was a predictor of survival in stage I lung adenocarcinomas ( P = 0.002). Conclusion: When tested in the Cox univariate proportional hazards model, RANTES expression by lung adenocarcinoma cells is a predictor of survival in stage I NSCLC patients and may be useful as a prognostic factor in lung cancer.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 1078-0432eISSN: 1557-3265Titel-ID: cdi_proquest_miscellaneous_72748442
- Format
- –
- Schlagworte
- Adenocarcinoma - genetics, Adenocarcinoma - metabolism, Adenocarcinoma - mortality, Biological and medical sciences, Carcinoma, Non-Small-Cell Lung - genetics, Carcinoma, Non-Small-Cell Lung - metabolism, Carcinoma, Non-Small-Cell Lung - mortality, Chemokine CCL4, Chemokine CCL5 - genetics, Chemokine CCL5 - metabolism, Chemokine CXCL10, Chemokines, CXC - genetics, Chemokines, CXC - metabolism, Gene Expression Profiling, Gene Expression Regulation, Neoplastic, Humans, Immunoenzyme Techniques, Interferon-gamma - genetics, Interferon-gamma - metabolism, Lung Neoplasms - genetics, Lung Neoplasms - metabolism, Lung Neoplasms - mortality, Lymphocyte Activation, Macrophage Inflammatory Proteins - genetics, Macrophage Inflammatory Proteins - metabolism, Medical sciences, Neoplasm Proteins - genetics, Neoplasm Proteins - metabolism, Neoplasm Staging, Oligonucleotide Array Sequence Analysis, Pneumology, Prognosis, RNA, Messenger - metabolism, Survival Rate, Tumors of the respiratory system and mediastinum